Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 3, 1998, Pages 807-813

  Di Somma, Carolina ^a   Colao, Annamaria ^a   Di Sarno, Antonella ^a   Klain, Michele ^a   Landi, Maria Luisa ^a   Facciolli, Giuseppina ^a   Pivonello, Rosario ^a   Panza, Nicola ^b   Salvatore, Marco ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; LUTEINIZING HORMONE; OSTEOCALCIN; PROLACTIN; QUINAGOLIDE; TESTOSTERONE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HUMAN; HYPERPROLACTINEMIA; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 15644381530     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.3.4674     Document Type: Article

References (29)

1. Klibanski A, Neer RM, Beitins IZ, Ridgway C, Zarvas NT, McArthur JW. 1980 Decreased bone density in amenorrheic women. N Engl J Med. 303:1511-1514.
2. Schlecthe JA, Sherman B, Martin R. 1983 Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab. 56:1120-1123.
3. Cann CE, Martin MC, Genant HK, Jaffe RB. 1984 Decreased spinal mineral content in amenorrheic women. JAMA. 251:626-630.
4. Koppelman MCS, Kurtz DW, Morrish KA, et al. 1984 Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab. 59:1050-1054.
5. Schlechte J, El-Khoury G, Kathol M, Walkner L. 1987 Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 64:1021-1026.
6. Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. 1992 Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 75:692-697.
7. Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G. 1990 Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest. 13:419-422.
8. Klibanski A, Greenspan SL. 1986 Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 315:542-546.
9. Toning O, Isberg B, Sjoberg HE, Bucht E, Hulting AL. 1993 Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol (Copenh). 128:423-427.
10. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. 1986 Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 104:77-82.
11. Wardlaw SL, Bilezikian JP. 1992 Hyperprolactinemia and osteopenia. J Clin Endocrinol Metab. 75:690-691.
12. Jackson JA, Kleerekoper M, Parfitt M. 1986 Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann Intern Med. 105:543-545.
13. Greenspan SL, Oppenheim DS, Klibanski A. 1989 Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 110:526-531.
14. Seeman E, Melton II LJ, O'Fallon WM, Riggs BL. 1983 Risk factors for spinal osteoporosis in men. Am J Med. 75:977-983.
15. Thorner MO, McNeilly AS, Hagan C, Besser GM. 1974 Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 2:419-422.
16. Murray FT, Cameron DF, Ketchum C. 1984 Return of gonadal function in men with prolactin-secreting pituitary tumors. J Clin Endocrinol Metab. 59:79-85.
17. Colao A, De Rosa M, Sarnacchiaro F, et al. 1996 Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol. 135:548-552.
18. Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F. 1988 Vertebral bone density in non amenorrhoic hyperprolactinemic women. Clin Endocrinol (Oxf). 28:1-6.
19. Kayath MJ, Lengyel AM, Vieira JG. 1993 Prevalence and magnitude of osteopenia in patients with prolactinoma. Brazil J Med Biol Res. 26:933-941.
20. Schlechte J, Walkner L, Kathol M. 1992 A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab. 75:698-703.
21. Delgrange E, Donkier J. 1997 Gonadal dysfunction in males with prolactinomas: from functional modification to irreversible damage? Eur J Endocrinol. 136:630.
22. Maktovic V, Ilich JZ, Skugor M, Saracoglu M. 1995 Primary prevention of osteoporosis. Phys Med Rehab Clin North Am. 6:595-627.
23. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. 1989 Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodelling. J Clin Endocrinol Metab. 69:523-527.
24. 6-GnRH). J Clin Endocrinol Metab. 76:288-290.
25. Wang C, Eyre DR, Clark D, et al. 1996 Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab. 81:3654-3662.
26. Katznelson L, Finkelstein JS, Schenfeld, Rosenthal DI, Anderson EJ, Klibanski A. 1996 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 81:4358-4365.
27. Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. 1985 Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obset Gynecol. 153:745-751.
28. Hui SL, Slemenda CW, Johnston Jr CC. 1989 Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med. 111:355-361.
29. Melton III LJ, Aktinson EJ, O'Fallon WM, Wahner HW, Riggs BL. 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1227-1234.